Harry Bushong
President

President and cofounder of nanoTox, Inc., Harry Bushong’s expertise includes work in the life sciences, raising capital for startups and leveraging value in intellectual property.

In 2003, Mr. Bushong worked with The Olmsted Group, a New York life sciences merchant bank with a licensed portfolio including Intellectual Property from Columbia University, Wisconsin University, MIT, Vanderbilt and Baylor College of Medicine in the fields of stem cells, genomics, biotech and hepatocytes. Mr. Bushong assisted several companies formed around a proprietary piece of intellectual property, including Omnimmune Corp., Plurion, Zirus (formerly Avatar), and Amphioxus. Amphioxus recently merged with Plurion to form Stem Cell Innovations, Inc. In addition, he worked with both public and private enterprises at Aurora Financial Services, a private NASD broker/dealer focused on the energy sector.

Mr. Bushong formed Wired Capital a private equity network series to assist early stage investors identify promising technological and industrial enterprises in Austin, Houston, Chicago, New York, San Francisco and Miami. He also helped transform a solutions management animation company into one of Austin’s earliest streaming media companies, securing three rounds of investments, a $3.5 Million encoding contract, and an international management team to promote the business model.

Mr. Bushong earned his National Association Of Securities Dealers Series 7 and 63 licenses while with Prudential Financial Services in Austin.
 
William Stahl
Chief Financial Officer

Certified Public Account William Stahl joined nanoTox in 2005 and has 34 years of experience in various companies and industries in increasingly complex financial management and accounting positions.

Prior to nanoTox, he had a private accounting practice and was CFO, Corporate Secretary and Corporate Treasurer for three separate start-up companies. Mr. Stahl was Senior Executive and CFO for an Austin, Texas-based indirect lender of consumer automobile contracts. Most notably, he led the Initial Public Offering of this firm, responsible for regulatory registrations and filings, negotiations and investment bankers. He managed all aspects of the firm’s financial operation and was instrumental in developing its financial and accounting infrastructure as it grew from 25 employees to over 125.

During Mr. Stahl’s ten years with the securities industry, he obtained Series 7 and Series 4 securities licenses and led the Financial Strategies support group of Westcap Securities serving more than 100 brokers primarily in asset-liability management for financial institutions.

Greg King
Chief Operations Officer

Gregory King joined nanoTox in 2008, bringing with him 30 years of international business and finance experience representing Fortune 500 companies throughout Europe, in Asia and in North and Latin America.

As Director of Corporate Treasury for Mitsubishi Heavy Industries’ largest U.S. subsidiary, Mr. King created a state of the art treasury operation, ensuring the appropriate financial structure for this capital goods manufacturer. In a joint venture with Citi Capital, he created a $1 billion retail finance program covering the U.S., Canada and major European countries.

He also arranged or provided financing for distributors in Mexico, Argentina, Chile, Venezuela and other Latin American countries. With Caterpillar, Inc., Mr. King’s responsibilities included foreign exchange management, management of Caterpillar Financial Services Corporation, financial representation to Latin America and exports to Europe and Asia. Mr. King also served on the Board of Directors for Rocla Oyj, Helsinki, Finland. Mr. King earned his Bachelors and Masters degrees in Business Administration from the University of Tennessee at Knoxville.

Dr. David W. Hobson
Chief Scientific Officer

Dr. David Hobson is a Principal at LoneStarPharmTox LLC. and a noted consultant to government and industry on product and technology development issues for dermatologic, wound healing and tissue repair therapeutics. He was formerly Vice President for Research and Development fot Chrysalis Biotechnology; Vice President of Medical Product Research and Development for Healthpoint, Ltd.; Director of Pharmaceutical Sciences at DPT Laboratories Ltd.; Vice President and a Research Fellow at Battelle Memorial Institute; and Director of Applied Toxicology for the Naval Medical Research Institute of the U.S. Navy.

Dr. Hobson is a Diplomat of the American Board of Toxicology and a Nuclear Medicine instructor at the University of the Incarnate Word in San Antonio, Texas. He has chaired and presented in nanotoxicology sessions at the Society of Toxicology and the Environmental Mutagen Society with an emphasis on early-stage recognition and resolution of nanotoxicology issues to support a developing and promising industry. Dr. Hobson has authored or co-authored several articles and book chapters on dermatoxicology, gastrointestinal toxicology, pharmacology and toxicology study design, nanomaterials safety, pharmaceutical manufacturing and product formulation, as other aspects of pharmaceutical research and development.

Dr. Hobson holds a Bachelor of Science degree from the University of Nebraska as well as Master of Science and Doctor of Philosophy degrees from Texas A&M University in Toxicology.